Form S-1 IPO & Registration Filings
Form S-1 is the initial registration statement filed by companies preparing for an Initial Public Offering (IPO) or registering new securities for public sale. It provides the first audited look at revenue growth, cohort retention, governance, and offering dilution.
- Pre-IPO revenue growth, gross margin profile, and path to profitability
- Use of proceeds, dual-class voting structures, and insider lock-up terms
- S-1/A pricing amendments disclosing target share price range and valuation
$ANT S-1 — Anthropic, PBC
One of the largest AI IPOs ever, pairing a public offering with a $26B strategic private placement and an unusual governance structure that cedes control to founders and a benef…
$RZRA S-1 — Rezera Inc.
A clinical-stage NLRP3 biotech with a GSK strategic interest is moving toward a Nasdaq IPO ahead of a pivotal Phase 3 PAD trial.
$SWA S-1 — Simwon America Corp.
A Tesla supply-chain manufacturer is moving toward a Nasdaq listing, with 40% of the offering coming from selling stockholders rather than the company.
$LIS S-1 — LIS Technologies Inc
A pre-revenue nuclear-fuel startup is testing public-market appetite for a speculative, capital-intensive enrichment technology with no commercial license yet.
$RZRA S-1 — Rezera Inc.
A clinical-stage biotech with a GSK-anchored ~10% indication of interest is bringing a novel oral NLRP3 inhibitor to public markets ahead of a pivotal Phase 3 trial.
$ANT S-1 — Anthropic, PBC
Anthropic's S-1 reveals the most governance-complex AI IPO ever: a public benefit corporation with a trust-controlled board and founder super-voting stock, testing whether publi…
$PARA S-1 — Parabolic Technologies, Inc.
This S-1 reveals a financing structure with aggressive warrant resets and a zero-exercise option that, combined with three reverse splits in 18 months, signals extreme balance-s…
S-1 — MED-X, INC.
A pre-revenue natural-products company with $38.1M raised privately is attempting a rare direct listing on Nasdaq Global Market — bypassing traditional IPO underwriting while ca…
$NUOX S-1 — NuvOx Therapeutics, Inc.
A clinical-stage biotech with three active trials and two orphan drug designations is testing whether an IPO can fund its pipeline through Phase II and into pivotal Phase III, d…
S-1 — Simwon America Corp.
A pure-play Tesla supplier with ~$50M IPO gives public-market investors direct exposure to Tesla's production ramp, but single-customer dependency and pending Nasdaq approval cr…
S-1 — Alopexx, Inc.
Amendment No. 20 signals a biotech IPO nearing the finish line after an unusually protracted SEC review, with a broad-platform pitch targeting a conserved pathogen antigen — a h…
$FFLY S-1 — FireFly Robotics, Inc.
A rare direct listing in the AgTech/robotics sector, bypassing traditional IPO underwriting while exposing investors to novel price-discovery mechanics and no guaranteed opening…
$GBC S-1 — GEORGIA BANKING CO INC
A $3.3B-asset regional bank using a direct listing (rather than a traditional IPO) is unusual in community banking and signals confidence in existing shareholder liquidity witho…
S-1 — LIS Technologies Inc
A pre-revenue nuclear-fuel startup with no commercial license and $65M in losses is testing public-market appetite on the back of U.S. policy shifts favoring domestic uranium en…
S-1 — Anthropic, PBC
Anthropic's S-1 reveals the most complex multi-class governance structure ever proposed in a major tech IPO, with public stockholders permanently locked out of board control in…
$BIAI S-1 — Bitari Inc
A small-cap Bitcoin mining infrastructure play seeking Nasdaq listing with a controlled-company structure and an AI data center pivot narrative, testing investor appetite at a ~…
S-1 — Aspen Neuroscience, Inc.
First pure-play autologous iPSC cell therapy for Parkinson's to file for IPO — if successful, sasineprocel would be the first disease-modifying PD treatment without immunosuppre…
S-1 — Bambusa Therapeutics, Inc.
A bispecific antibody developer with early positive atopic dermatitis efficacy data is seeking a Nasdaq IPO, offering exposure to a projected $200 billion immunology market.